More Videos
|
CNBC'S MOST SHARED
- Unemployed? Bored? Make Money Playing Beer Pong
- Social Networking's 'Naked' Truth
- The Highest Grossing (Inflation Adjusted) Movies of All Time
- WPP's Sir Martin Sorrell on the Ad Recession
- Geek Squad V. Gizmodo
- Merrill's McCann Seen as UBS Wealth Frontrunner
- Warren Buffett's Top Three Investment Rules for the Average American
- Why You Should Watch Fund Flows
- Blog You!!!
- Eric Schmidt on Government Scrutiny and Economic Recovery
- Market 360: The Week's Best & Worst
- Geek Squad V. Gizmodo
- Brandt: Google Chrome OS in the Post-PC Age
- Other People Are Weirder Than We Are
- Bank Failures: Is The Nightmare Over? (Video)
- California Here I Go? No.
- Roginsky: No More Mr. Nice Guy
- Commercial Conundrum
- Stimulus Will Kick in Later this Year: President Obama
- Lender CIT Group Hires Premier Bankruptcy Adviser
- Government Selling Bank Stakes for Too Cheap: Panel
- Buffett's Top 3 Investment Rules for Average Americans
- Market Insider: Earnings Loom in the Week Ahead
- Bulls Get Summertime Blues, But It's Hot Fun for Bears
- As Banks Fail, Strong Institutions Become More Visible
- GM IPO in Second Quarter 2010 at the Earliest: CFO
- Merrill's McCann Seen as UBS Wealth Frontrunner
RSS FEED
Text Size 
I've blogged many times about the embargoes imposed by scientific groups and medical journals. If a media outlet breaks one -- something I have not done -- they risk losing the "privilege" of receiving the info ahead of time. And there's been a recent example of a prominent doctor who spoke too soon and has been barred for a while from publishing and reviewing studies in a peer-reviewed journal. Well, now at least one organization may take the enforcement a step further.
Reuters broke the story that three research analysts -- one at Merrill Lynch, another at Natexis Bleichroeder and the third at JPMorgan -- issued reports earlier this week with embargoed data from the upcoming American Academy of Neurology conference.
Two of the research notes to clients were about an experimental Alzheimer's drug from Baxter [BAX
Loading...
()
]. And the other note focused on the MS drug Tysabri from BIIB [BIIB
Loading...
()
] and ELN [ELN
Loading...
()
].
Reuters says the JPM and Natexis reports were retracted or recalled and that Merrill declined to comment.
But a spokesperson for the AAN says the recall or retraction may not be sufficient and that the organization could possibly try to take some kind of legal action. Here's their statement:
“The American Academy of Neurology is disappointed that representatives of financial organizations have deliberately violated the Academy’s embargo policy. The violation has been referred to the Academy’s General Counsel who is currently exploring all options available to the Academy.”
The embargo issue keeps cropping up for the organizations and journals that are trying to protect their "scientific integrity" and potentially headline-making content while servicing the companies that often sponsor the research (and the conferences) and in which Wall Street has a vested interest.
It will once again be put to the test over the next couple of months when the most widely-followed conference by doctors, scientists, investors, reporters and analysts--the American Society of Clinical Oncology annual meeting--employs a new policy this year with some of its data to try to satisfy everyone.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes